NASDAQ:ONCT

Oncternal Therapeutics Stock Forecast, Price & News

$6.43
-0.33 (-4.88 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.08
Now: $6.43
$6.80
50-Day Range
$5.19
MA: $7.54
$9.39
52-Week Range
$1.49
Now: $6.43
$10.56
Volume2.98 million shs
Average Volume1.74 million shs
Market Capitalization$317.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical need. Its pipeline includes cirmtuzumab, an investigational monoclonal antibody that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia. The company also develops a chimeric antigen receptor T cell therapy that targets Receptor tyrosine kinase-like Orphan Receptor 1, which is in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, it is developing TK216, an investigational small molecule that inhibits the E26 Transformation Specific family of oncoproteins. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; Shanghai Pharmaceutical (USA) Inc.; Selexis S.A.; and University of Tennessee Research Foundation. The company is headquartered in San Diego, California.
Oncternal Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONCT
CUSIPN/A
CIKN/A
Phone858-434-1113
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.42 million
Book Value$0.93 per share

Profitability

Net Income$-34,190,000.00
Net Margins-746.10%

Miscellaneous

Market Cap$317.41 million
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Oppenheimer
April 13, 2021 |  americanbankingnews.com
Oncternal Therapeutics: Q4 Earnings Snapshot
March 11, 2021 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

289th out of 2,016 stocks

Pharmaceutical Preparations Industry

127th out of 771 stocks

Analyst Opinion: 4.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$6.43
-0.33 (-4.88 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oncternal Therapeutics (NASDAQ:ONCT) Frequently Asked Questions

Is Oncternal Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oncternal Therapeutics stock.
View analyst ratings for Oncternal Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Oncternal Therapeutics?

Wall Street analysts have given Oncternal Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncternal Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oncternal Therapeutics?

Oncternal Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 211,300 shares, an increase of 136.6% from the February 28th total of 89,300 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is currently 0.1 days.
View Oncternal Therapeutics' Short Interest
.

When is Oncternal Therapeutics' next earnings date?

Oncternal Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Oncternal Therapeutics
.

How were Oncternal Therapeutics' earnings last quarter?

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) issued its quarterly earnings results on Thursday, March, 11th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.09. Oncternal Therapeutics had a negative net margin of 746.10% and a negative trailing twelve-month return on equity of 150.58%.
View Oncternal Therapeutics' earnings history
.

What price target have analysts set for ONCT?

5 analysts have issued 12 month price targets for Oncternal Therapeutics' stock. Their forecasts range from $9.00 to $21.00. On average, they anticipate Oncternal Therapeutics' stock price to reach $15.20 in the next twelve months. This suggests a possible upside of 136.4% from the stock's current price.
View analysts' price targets for Oncternal Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Oncternal Therapeutics' key executives?

Oncternal Therapeutics' management team includes the following people:
  • Dr. James B. Breitmeyer, Pres, CEO & Director (Age 67, Pay $726.84k)
  • Mr. Richard G. Vincent, CFO, Treasurer & Sec. (Age 57)
  • Dr. Rajesh Krishnan Ph.D., Chief Technology Officer
  • Dr. Gunnar F. Kaufmann Ph.D., Chief Scientific Officer (Age 45)
  • Dr. Edwina Baskin-Bey, Acting Chief Medical Officer

Who are some of Oncternal Therapeutics' key competitors?

What other stocks do shareholders of Oncternal Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), The Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX).

What is Oncternal Therapeutics' stock symbol?

Oncternal Therapeutics trades on the NASDAQ under the ticker symbol "ONCT."

How do I buy shares of Oncternal Therapeutics?

Shares of ONCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncternal Therapeutics' stock price today?

One share of ONCT stock can currently be purchased for approximately $6.43.

How much money does Oncternal Therapeutics make?

Oncternal Therapeutics has a market capitalization of $317.41 million and generates $2.42 million in revenue each year. The company earns $-34,190,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Oncternal Therapeutics have?

Oncternal Therapeutics employs 12 workers across the globe.

What is Oncternal Therapeutics' official website?

The official website for Oncternal Therapeutics is www.oncternal.com.

Where are Oncternal Therapeutics' headquarters?

Oncternal Therapeutics is headquartered at 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130.

How can I contact Oncternal Therapeutics?

Oncternal Therapeutics' mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-434-1113 or via email at [email protected]


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.